Catalyst
Slingshot members are tracking this event:
ZIOPHARM Announces First Patient Enrolled in Phase 1 Study of Second Generation Non-Viral CD19-Specific CAR T-Cell Therapy for Advanced Lymphoid Malignancies
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| ZIOP | Community voting in process | |||||
Additional Information
In two prior trials the first generation CD19-specific CAR+ T cells, patient-derived (autologous) or donor-derived (allogeneic) T cells were administered to recipients with advanced CD19-expressing leukemias and lymphomas after hematopoietic stem-cell transplantation (HSCT). Results demonstrated an apparent doubling of survivals compared to historical controls.The second-generation Sleeping Beauty CAR+ T cells employ a revised CAR construct designed to improve persistence and anti-tumor response over the first generation therapy. Additionally, this investigational treatment is independent of HSCT.
Slingshot Insights Explained
Catalyst Date
Occurred on:
Feb 09, 2016
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Phase 1 Study, Cd19, Car T-cell Therapy, Advanced Lmphoid Malignancies
